Targeting protein degradation strategies in drug discovery: integrating PROTACs, ubiquitination biology, and AI-driven design
Targeted protein degradation (TPD) has emerged as a transformative therapeutic strategy for eliminating disease-associated proteins, including targets that remain challenging to modulate using conventional occupancy-driven inhibitors. Among TPD approaches, proteolysis-targeting chimeras (PROTACs) exploit the ubiquitin–proteasome system (UPS) to induce selective and event-driven degradation of proteins of interest (POIs). Despite rapid advances in PROTAC development, successful translation depends on interconnected determinants, including target degradability, ubiquitin ligase (E3) recruitment, warhead and linker properties, ternary-complex formation, ubiquitination efficiency, intracellular exposure, and pharmacokinetic behavior. This review provides an integrated, mechanism-oriented analysis of these determinants by linking PROTAC design, ubiquitination biology, computational approaches, and clinical development. We examine key principles governing PROTAC-mediated degradation, with emphasis on E3-ligase selection, linker design, ternary-complex geometry and cooperativity, ubiquitin (Ub)-acceptor lysine (Lys) accessibility, ubiquitin-conjugating enzyme (E2)/E3 context, proteasomal engagement, inefficient degradation, and the hook effect. Recent advances in artificial intelligence (AI) and machine learning for degradation-activity prediction, E3-ligase/POI pairing, ligand and linker optimization, ternary-complex modeling, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessment are critically evaluated alongside their technical and translational limitations. Preclinical developments, clinical-stage degraders, emerging TPD modalities, and major barriers to translation are also discussed. We propose an integrated framework linking distinct target ubiquitination patterns, degrader design, ternary-complex geometry, AI-enabled prediction, and pharmacokinetic/clinical constraints, providing a mechanism-informed roadmap for the rational development of next-generation protein degraders and identifying mechanistic bottlenecks and translational priorities across therapeutic settings.
Authors
- Chandra Sekhar Bhol (ORCID: https://orcid.org/0000-0003-3397-6483)
- Gautam Sethi (ORCID: https://orcid.org/0000-0002-8677-8475)
- Li Wang (ORCID: https://orcid.org/0000-0003-2452-0169)
- Sanjeevi Pandiyan
Institutions
- National University of Singapore (SG)
- Nantong University (CN)
Publication Details
- Journal
- Molecular Biomedicine
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s43556-026-00649-4
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00